Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function
- PMID: 11591118
- DOI: 10.1006/cimm.2001.1835
Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function
Abstract
Induction of heterosubtypic immunity to influenza viral antigens is of paramount importance to the prevention of epidemics and potential pandemics. The 1997 incidence of avian influenza infections in humans in Hong Kong heightened the need for pandemic preparedness and a search for vaccines and vaccine delivery systems that can confer broad protection. In this report, we demonstrate that the delivery of H1N1 subtype influenza viral antigens as immunostimulating complexes (ISCOM) induces broad cross-protection in mice against challenge with various influenza virus subtypes, including the avian H9 and the H5 strains that were recently responsible for deaths in humans. The ISCOM delivery system induced high and long-lived serum antiviral antibodies and class I-restricted cytotoxic T-lymphocytes (CTL). Studies with perforin, IFN-gamma, and mu-chain gene knock-out mice demonstrated that the heterosubtypic protection required cross-reactive, functional cytotoxic T cells and nonhemagglutination inhibiting serum antibodies. Interferon-gamma, a major player in viral clearance by nonlytic mechanisms, did not appear to play a role in heterosubtypic immunity. Nonformulated H1N1 influenza antigens failed to induce significant CTL or long-lasting antibody responses or to protect mice against challenge with heterosubtypic viruses. Furthermore, while influenza virus infection induced a dominant nucleoprotein (NP)-specific CTL response in H2 mice, the ISCOM delivery system induced a dominant hemagglutinin-specific CTL response. Moreover, non-neutralizing but cross-reactive antibodies played a role in reducing viral titers by macrophages. These results suggest that exogenous delivery of influenza antigens as ISCOM can influence their antigen processing and presentation, their ability to induce/recall CTL specificities, and their capacity to mediate broad cross-protection against influenza virus variants.
Copyright 2001 Academic Press.
Similar articles
-
Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.Vaccine. 2009 Aug 6;27(36):4983-9. doi: 10.1016/j.vaccine.2009.05.079. Epub 2009 Jun 16. Vaccine. 2009. PMID: 19538996
-
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues.Virology. 1999 Feb 1;254(1):50-60. doi: 10.1006/viro.1998.9521. Virology. 1999. PMID: 9927573
-
A CTL-based liposomal vaccine capable of inducing protection against heterosubtypic influenza viruses in HLA-A*0201 transgenic mice.Biochem Biophys Res Commun. 2010 Jan 15;391(3):1494-9. doi: 10.1016/j.bbrc.2009.12.100. Biochem Biophys Res Commun. 2010. PMID: 20060099
-
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.Jpn J Infect Dis. 2005 Aug;58(4):195-207. Jpn J Infect Dis. 2005. PMID: 16116250 Review.
-
Pandemic preparedness: toward a universal influenza vaccine.Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Drug News Perspect. 2009. PMID: 19330167 Review.
Cited by
-
Seasonal H1N1 influenza virus infection induces cross-protective pandemic H1N1 virus immunity through a CD8-independent, B cell-dependent mechanism.J Virol. 2012 Feb;86(4):2229-38. doi: 10.1128/JVI.05540-11. Epub 2011 Nov 30. J Virol. 2012. PMID: 22130540 Free PMC article.
-
Mucosal immunity: overcoming the barrier for induction of proximal responses.Immunol Res. 2004;30(1):35-71. doi: 10.1385/IR:30:1:035. Immunol Res. 2004. PMID: 15258310 Review.
-
Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.Influenza Other Respir Viruses. 2020 Jan;14(1):92-101. doi: 10.1111/irv.12697. Epub 2019 Nov 27. Influenza Other Respir Viruses. 2020. PMID: 31774251 Free PMC article. Review.
-
Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles.PLoS One. 2011;6(6):e21522. doi: 10.1371/journal.pone.0021522. Epub 2011 Jun 29. PLoS One. 2011. PMID: 21747909 Free PMC article.
-
Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.Virol J. 2008 Mar 20;5:44. doi: 10.1186/1743-422X-5-44. Virol J. 2008. PMID: 18355405 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous